First-line targeted therapy shows antitumor activity in patients with advanced lung cancer

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), providing a safe and effective oral targeted treatment alternative to chemotherapy, according to researchers at The University of Texas MD Anderson Cancer Center.